	Application No.	Applicant(s)	
Notice of Allowability	09/177,711	ADAMS ET AL.	
	Examiner	Art Unit	
	Shengjun Wang	1617	
The MAILING DATE of this communication appears on the cover sheet with the correspondence address All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice of Allowance (PTOL-85) or other appropriate communication will be mailed in due course. THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS. This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308.			
<ol> <li>This communication is responsive to 12/29/03.</li> <li>The allowed claim(s) is/are 60-62,64-69 and 112-122.</li> <li>The drawings filed on are accepted by the Examiner</li> <li>Acknowledgment is made of a claim for foreign priority une</li> <li>a) All b) Some* c) None of the:         <ol> <li>Certified copies of the priority documents have</li> <li>Certified copies of the priority documents have</li> <li>Copies of the certified copies of the priority documents have</li> <li>Copies of the certified copies of the priority documents have</li> </ol> </li> <li>* Certified copies not received:</li> <li>Acknowledgment is made of a claim for domestic priority under reference was included in the first sentence of the specification of the foreign language provisional and Acknowledgment is made of a claim for domestic priority under the first sentence of the specification or in an Application</li> <li>Acknowledgment is made of a claim for domestic priority under the first sentence of the specification or in an Application</li> </ol>	been received.  been received in Application been received in Application been received in Application been received ander 35 U.S.C. § 119(e) (to antion or in an Application Da application has been received	on No  Indicate the distance of the di	specific
Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application. THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.  7. A SUBSTITUTE OATH OR DECLARATION must be submitted. Note the attached EXAMINER'S AMENDMENT or NOTICE OF			
INFORMAL PATENT APPLICATION (PTO-152) which gives reason(s) why the oath or declaration is deficient.  8.  CORRECTED DRAWINGS (as "replacement sheets") must be submitted.  (a) including changes required by the Notice of Draftsperson's Patent Drawing Review (PTO-948) attached  1) hereto or 2) to Paper No  (b) including changes required by the proposed drawing correction filed, which has been approved by the Examiner.  (c) including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No			
Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the margin according to 37 CFR 1.121(d).  9. DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the			
attached Examiner's comment regarding REQUIREMENT FOR T	HE DEPOSIT OF BIOLOG	ICAL MATERIAL.	
Attachment(s)			
1  Notice of References Cited (PTO-892) 2  Notice of Draftperson's Patent Drawing Review (PTO-948) 3  Information Disclosure Statements (PTO-1449 or PTO/SB/08 Paper No.  □4/□2/□2 4  Examiner's Comment Regarding Requirement for Deposit of Biological Material	6☐ Interview Su ), 7☐ Examiner's	formal Patent Application (PTO-15) Immary (PTO-413), Paper No Amendment/Comment Statement of Reasons for Allowand	<u></u> .

## **DETAILED ACTION**

The amendments, and the request for consideration filed December 29, 2003 have been received and entered into the file.

Applicant's amendment distance the instant the claims herein from the prior art methods, and use. An exhaustive literature search failed to produce any reference to claimed compounds for the use herein claimed. Although some compounds claimed by applicant, reside in the prior art, the prior art use fails to state, or suggest the use herein claimed.

Particularly, the unexpected benefits residing in the claimed method convincingly distance the claimed method from the prior art. It would not be obvious for the skilled artisan to employ the claimed compounds concomitantly and expect the therapeutic effect herein illustrated. It is noted that the applicant has illustrated a representative sample of the claimed active ingredient group, thereby illustrating the unexpected results for such a grouping. The skilled artisan would not expect the claimed compounds to produce the illustrated pharmacological effect, claimed herein, in view of the enclosed showing.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Shengjun Wang, Ph.D. whose telephone number is (703) 308-4554. The examiner can normally be reached on Monday-Friday from 8:30 to 5:00.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Sreeni Padmanabhan, can be reached on (703) 305-1877. The fax phone number for the organization where this application or proceeding is assigned is (703) 308-4556.

Art Unit: 1617

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (703) 308-1235.

Primary Examiner

Shengjun Wang

January 14, 2004